RUNX1/EGFR/STAT3 signaling pathway should be considered as a target for the therapy of TSC, because the abnormal activation of mTORC1 enhances the signal of RUNX1/EGFR/STAT3 to promote tumorigenesis [13]. Here, EGFR is linked to tuberous sclerosis.